PeriVision SA: Company Research Report

Company Overview

• Name: PeriVision SA

• Mission: To make eye testing and care accessible to everyone everywhere by combining artificial intelligence (AI), virtual reality (VR), and the cloud to create next-generation systems for testing and understanding visual function.

• Founded: 2022

• Founders: Patrick Kessel, Dr. Serife Kucur Ergunay, Prof. Dr. Raphael Sznitman

• Key People:

• Patrick Kessel: Co-founder, CEO & Board Member

• Dr. Serife Kucur Ergunay: Co-founder, CTO & Board Member

• Prof. Dr. Raphael Sznitman: Co-founder & Board Member

• Kevin Gillmann: Chief Medical Officer

• Benedetto Sgroi: Chief Commercial Officer

• Walter Inäbnit: Investor & Board Observer

• Dr. Ernest Cavin: Board Member

• Headquarters:

• Switzerland: Biopole Phenyl Building, Route de la Corniche 3, CH-1066 Epalinges

• USA: One Broadway & 245 Main Street, Cambridge, MA 02142

• Number of Employees: No information is available.

• Revenue: No information is available.

• What is the Company Known For: PeriVision is recognized for its innovative approach to eye care using AI, VR, and cloud computing to modernize and improve eye testing methods, particularly for glaucoma diagnosis and monitoring.

Products

VisionOne™

• Description: VisionOne™ is a VR visual field platform tailored for diagnosing and monitoring glaucoma. It is renowned for its industry-leading speed and accuracy.

• Key Features:

• AI and VR Integration: Utilizes AI algorithms to optimize testing, providing automation assistance, quality control, and valuable insights for clinical decisions.

• Portability: Configurable eye tests on portable VR headsets.

• Cloud-Based: Analyzes results on a cloud platform enhancing clinic productivity.

• Patient Experience: Enhanced by features such as a virtual assistant, fast AI perimetry, eye tracking, custom lens holder, and easy-to-use patient clicker.

• Efficiency: Up to 39% reduction in inter-test variability and 1.30 dBs test-retest variability.

Recent Developments

• New Products Launched: VisionOne™ platform registered with the US FDA.

• New Features Added: VisionOne™ features cloud-platform analysis of VR-based eye tests, optimized by patented AI technology.

• Partnerships and Collaborations:

• Partnered with Von Hoff for distribution in Swiss and Liechtenstein markets.

• Collaborated with the Inselspital Ophthalmology Department to clinically validate their technology.

• Awards & Grants:

• Received CHF 1.1 million for developing functional eye tests for retina diseases.

• Awarded the EIT Health Wild Card with EUR 1.5 million.

• Received the Innosuisse Certificate indicating readiness for sustainable growth and investment.

Additional Information

• Regulatory Approvals: VisionOne™ has been registered with the US FDA, marking a significant milestone in PeriVision’s commitment to safety, efficacy, and quality in medical software.

In summary, PeriVision SA has positioned itself as a significant player in the eye care technology sector by blending the power of AI, VR, and the cloud to innovate vision testing for the future. The company’s strategic partnerships, clinical validations, and regulatory approvals highlight its potential to transform glaucoma care globally.